<DOC>
	<DOCNO>NCT00001002</DOCNO>
	<brief_summary>To study toxicity , pharmacokinetics , antiretroviral effectiveness combine oral zidovudine ( AZT ) intermittent intravenous foscarnet therapy stable AIDS AIDS relate complex ( ARC ) patient already receive AZT 8 - 52 week . It hypothesize maximum AZT antiretroviral effect , occur 8 week therapy , enhance 2 week foscarnet treatment , give time intermittent intravenous infusion . In addition , lower serum p24 antigen concentration occur combine therapy might continue oral AZT therapy continue without foscarnet .</brief_summary>
	<brief_title>A Study Foscarnet Treatment HIV Infection Patients Who Have Taken Zidovudine Long Time</brief_title>
	<detailed_description>It hypothesize maximum AZT antiretroviral effect , occur 8 week therapy , enhance 2 week foscarnet treatment , give time intermittent intravenous infusion . In addition , lower serum p24 antigen concentration occur combine therapy might continue oral AZT therapy continue without foscarnet . There 4-week prestudy monitoring period AZT alone administer outpatient basis , follow 2-week study period intravenous foscarnet oral AZT administer hospital . During subsequent 6-month follow-up period , oral AZT administer patient receive clinical evaluation . AZT hold 48 hour day hospitalization 24 hour end hospitalization .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Medication necessary patient 's welfare discretion investigator . Patients must follow : Received zidovudine ( AZT ) 200 mg every 4 hour ( q4h ) continuously 8 16 week without Grade 3 high toxicity . Detectable p24 antigen serum least 2 occasion prestudy period . All serum p24 antigen concentration measure prestudy period must least twice concentration cutoff value assay . Capability give informed consent . Per amendment 890721 , patient must enter study period September 30 , 1989 . Exclusion Criteria Coexisting Condition : Patients follow exclude : A history hypersensitivity reaction foscarnet zidovudine ( AZT ) . History Grade 3 4 toxicity AZT . Current Grade 2 high AZT toxicity . Osteomalacia , neoplasm metastatic bone , know bone disease . Active opportunistic infection require myelosuppressive nephrotoxic therapy . Concurrent Medication : Excluded : Antimetabolites . Immunomodulators . Nephrotoxins . Antiviral therapy . Myelosuppressive nephrotoxic therapy . Acetaminophen . Patients follow exclude : A history hypersensitivity reaction foscarnet zidovudine ( AZT ) . History Grade 3 4 toxicity AZT . Current Grade 2 high AZT toxicity . Osteomalacia , neoplasm metastatic bone , know bone disease . Active opportunistic infection require myelosuppressive nephrotoxic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>